Free Trial
NASDAQ:IDRA

Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.17
$7.23
52-Week Range
N/A
Volume
21,870 shs
Average Volume
464,030 shs
Market Capitalization
$450.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IDRA stock logo

About Idera Pharmaceuticals Stock (NASDAQ:IDRA)

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

IDRA Stock News Headlines

Ekso Bionics (NASDAQ: EKSO)
Kiniksa Pharmaceuticals
I’m giving you the name of this investment for free
I want to help you achieve that right by accessing a new business model in America that has been unlocked by a billionaire who may end up sitting in Trump’s cabinet.
Nabriva Therapeutics AG (NBRVF)
Marginalia
I’m giving you the name of this investment for free
I want to help you achieve that right by accessing a new business model in America that has been unlocked by a billionaire who may end up sitting in Trump’s cabinet.
Idera Pharma Acquires Rare Disease Player, Names New CEO
Idera Pharmaceuticals Acquires Aceragen
Idera Pharmaceuticals Stock (NASDAQ:IDRA), Dividends
See More Headlines
Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
7/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IDRA
Employees
32
Year Founded
1989

Profitability

Net Income
$98.09 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.56 per share

Miscellaneous

Free Float
59,206,000
Market Cap
$450.52 million
Optionable
Optionable
Beta
1.25

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives


IDRA Stock Analysis - Frequently Asked Questions

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01.

When did Idera Pharmaceuticals' stock split?

Idera Pharmaceuticals shares split before market open on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly created shares were distributed to shareholders after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Idera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Idera Pharmaceuticals investors own include Oasis Petroleum (OAS), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Dynavax Technologies (DVAX), Proteostasis Therapeutics (PTI) and Geron (GERN).

This page (NASDAQ:IDRA) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners